



Figure S1: <sup>1</sup>H-NMR spectrum of compound 5




<sup>1</sup>H-NMR for compound 5.

Figure S2:  $^{13}\text{C}$ -NMR spectrum of compound 5



$^{13}\text{C}$ -NMR for compound 5.

Figure S3: HR-Mass spectrum of compound 5.





**Table**  
**Primer**

|    |                |                                                                       |                          |                           |            |
|----|----------------|-----------------------------------------------------------------------|--------------------------|---------------------------|------------|
| 1. | <i>ct</i>      | Encodes for cholera toxin                                             | TATGCCAAGAGGACAGA GTGAG  | AACATATCCATCATCGT GCCTAAC | 28         |
| 2. | <i>tcp</i>     | Encodes for toxin co-regulated pili-Adhesion                          | CGTTGGCGGTCAGTCTT G      | CGGGCTTTCTTCTTGTT CG      | 28         |
| 3. | <i>hapA</i>    | Protease - Dissemination of <i>V. cholerae</i> from host intestine    | ACGGTACAGTTGCCGAA TGG    | GCTGGCTTTCAATGTCA GGG     | 29         |
| 4. | <i>hapR</i>    | Inhibition of biofilm formation                                       | CCAACTTCTTGACCGAT CAC    | GGTGGAAACAAACAGT GGCC     | 30         |
| 5. | <i>aphA</i>    | Regulation of virulence genes and quorum sensing                      | GCAGAACCTTACCGTCT GCAA   | GCGTAATAAGCGGCTT CGATT    | This study |
| 6. | <i>qrr-4</i>   | Small regulator RNA- along with Hpq binds to hapR- repression of HapR | TGACCCTTCTAAGCCGA GGG    | GAACAATGGTGTTTCAACG       | 31         |
| 7. | <i>16srRNA</i> | DNA cell repair and cell division                                     | ACCTTACCTACTCTTGA CATCCA | TACACATACAGTTGGA TTGC     | 14         |

**S1.**

sequence used for quantitative PCR



**FigureS4(a): Synergy  
QSI<sup>py</sup> with doxycycline  
HYR14.**

analysis of

and

ciprofloxacin

against

strain

HYR14.

The percentage inhibition measured for QSI<sup>py</sup> (0–3.9 µg/mL) in combination with doxycycline (4 µg/mL, panel a) and ciprofloxacin (0.5 µg/mL) revealed no significant difference between the antibiotic alone and the combination treatments. (n=3, ns: not significant, \*p < 0.05)

**FigureS4(b): Synergy analysis of QSI<sup>Py</sup> with doxycycline and ciprofloxacin against strain MTCC3906.**

The percentage inhibition measured for QSI<sup>Py</sup> (0–3.9 µg/mL) in combination with doxycycline (4 µg/mL, panel a) and ciprofloxacin (0.5 µg/mL) revealed no significant difference between the antibiotic alone and the combination treatments. Data represent mean  $\pm$  SD; (n=3, ns: not significant, \*p < 0.05, \*\*\*p<0.001, \*\*\*\*p<.0001)

